tryingtomakesenseofpeople:

darqueste-grimoire:

prettysoldiersailorbri:

somegrumpystrayanbastard:

http://mic.com/articles/106838/watch-one-brave-woman-confront-manspreaders-on-the-new-york-city-subway

"Your balls aren’t that big"

Well, how about taking into account that a male pelvis is a completely different shape altogether? Thus, the hip joint and femur protrude at completely different angles between the sexes, thus the tendency for the habit of men sitting with their legs apart, and vice versa.

Not only this, but the reason a mans nuts sit outside the body is so air can circulate, as the happy little DNA in there can survive at only a specific temperature. Hence a guy sitting with his legs open by default.

It’s not privilege, it’s anatomy you self entitled whinging fucking morons, and if anyone stopped and fucking looked at this shit before they kicked up a fucking campaign of shaming people just because of their fucking anatomy, maybe the shit of a campaign wouldn’t have gotten any publicity.

If someone won’t shift their legs in public for you to sit down, fair enough, ask them to do so. But just going up to guys sitting around and shaming them for the natural, default way of sitting just because you think it’s their “male privilege” if completely and utterly deplorable.
Fuck right off.

Okay, you want to claim biology? You really want to do that? Firstly, where are your receipts? I want to know how much research you’ve done into this—how long DO balls need to be aerated? How often? What specific temperatures are the golden ratio in order to prevent spermatogenesis arrest? I highly doubt you can claim that men need to let their testes breathe 24 hours a day. Do you carry a thermometer in your pants all the time to make sure your balls are at the optimal temperature? I highly doubt that, as well.

If we’re going to use biology as an excuse, then why would gay men, for example, need their balls aerated as well? Why not restrict your balls-in-the-open policy if you’re so concerned about spermatogenesis arrest? What about those men out there who don’t want to procreate at all? What about asexual men? What’s their excuse if they’re not going to use their body as biology intends?

If we’re going to use biology as an excuse, why aren’t tampons or pads for menstruation subsidized for women? Why can’t women breastfeed in public? Why is their social stigma against body hair on women? Why is the government preventing women healthy and safe access to abortions? Why don’t women have the same amount of control over their bodies with regards to their biological processes? If you’re concerned about biology, then go the whole hog and bitch about these problems, too. These are actual issues women face, and that’s scratching the surface. Or could it be that you only care about your “rights” to taking up 4 seats on public transit or in public spaces so much that you use bullshit excuses like “biology”? (“Biology” in quotations as I do doubt that your research has gone any further into the matter than a cursory glance at Wikipedia—which, by the way, is liberally peppered with [citation needed].)

Even if we go beyond biology, how about the fact that it is simple common courtesy for others in public spaces? If you’re an adult in the world, there are unspoken social contracts out there that dictate you behave in a socially acceptable manner. Okay, yes, this has been deemed socially acceptable by default in the past, but you know what else was? Child labor. Unregulated food and drugs. Just to name a few. The game’s changed, pal. We’re wising up to your shit, and we are tired of our space being constantly infringed upon by oblivious, self-concerned, privileged (yes, privileged) men who think it’s socially acceptable to take up multiple seats in public and gracing us all with ball sweat stench just because of “biology”. Do you even need all that room? Why must you do that in public?

I assure you, if I needed to change my tampon in public or breastfeed a baby out in the open, there’d be hell to pay. But why not in your case? Just because your balls are precious, like society has told you your whole life? Women have been told so much that we should take up less space—be thin and svelte, cross your ankles like a lady, for god’s sake don’t open your legs you look like a whore, &c. Have you heard of yeast infections? Because I can tell you, aerating my vagina will certainly help prevent that. So maybe I should start taking a leaf outta your page. Honestly, if you’re concerned about your balls that much, you need to go to a doctor stat. We’ve tried asking y’all nicely to stop. I doubt many of us will ask nicely the second time around.

I see you did not counter argue the anatomical structure of a male’s pelvis, interesting, thus I will not source that for you, as you appear happy with that. In the talk of spermatogenesis, the process of spermatogenesis is highly sensitive to fluctuations in the environment, particularly hormones and temperature. Testosterone is required in large local concentrations to maintain the process, which is achieved via the binding of testosterone by androgen binding proteins present in the seminiferous tubules. Testosterone is produced by interstitial cells, also known as Leydig cels, which reside adjacent to the seminiferous tubules. Seminiferous epithelium is sensitive to elevated temperature in humans and some other species, and will be adversely affected by temperatures as high as normal body temperature. Consequently, the testes are located outside the body in a sack of skin called the scrotum. The optimal temperature is maintained at 2 °C (Adult human male)–8 °C (Adult male mouse) below body temperature. This is achieved via regulation of blood flow and positioning towards and away from the heat of the body by the cremasteric muscle and the dartos smooth muscle in the scrotum.
Further Reading (If you’re interested): 
 - Why the testes have evolved to be descended scrotal testicles

Also I am asexual, and would still enjoy having offspring of my own one day, thus I am keeping my testes, thank you for your concerning presumptions however that just because we do not wish to have sex, does not imply we do not wish to reproduce. This can also be said for Homosexual males whom wish to have their own biological children, via IVF. 

In consideration of the points you’ve raised for ‘Biological issues that females face’, I assume your country has yet to allow those rights to you and your sisters, however you cannot counter-argue a global biological factor against your national lack of rights, correct? As I recall, in Britain contraception is in abundance and abortion is allocated to those who wish to have it (Albeit are still harassed by the idiots you’ll find protesting outside of them) due to the The Abortion Act of 1967, an Act of the Parliament of the UK legalising abortions by registered practitioners, and regulating the free provision of such medical practices through the National Health Service (NHS). Also I believe feminine hygiene products are not subsidised because they can get a great profit from them, companies can make products in varying qualities with varying expenses and can always fork in a profit because they are necessary - quite logical in my opinion, a cruel form of earning profit, but logical.

I’m quite unsure of your concluding paragraph (If it can be called a conclusion), for one thing I do not recall women ever being implicitly or explicitly told to take up less space, in fact it’s quite the contrary as females with offspring who get aboard a bus are usually given quite a lot of space for their pram and themselves (It’s rare for a male to be with their offspring from what I’ve observed taking my buses day-to-day [I usually see them carrying the child rather than using a pram] but I’m sure they are allocated as much room), and so that they may handle the child without interfering with the others aboard the bus. Also what is this about crossing ankles? If it’s an idiom I will not understand it but I have never heard such a trivial thing typed out afore, actually scratch that, I’ve not heard it in any format ‘til now.

Yeast Infections - Candidal vulvovaginitis;
You state that the aeration of your vagina will ‘certainly’ prevent it, however upon researching it aeration is not even a considered treatment neither preventative measure so where you are getting your sources I do not know, if you could source me with an article stating how natural atmospheric air helps prevent candidal vulvovagintis rapidly forming colonies that would be great, if not allow me to source you with the causes, and how to properly treat it rather than your unusual preventative method of aeration.
  Candidal vulvovaginitis or vaginal thrush, is an infection of the vagina’s mucous membranes via candida albicans. Signs and symptoms include: vaginal itching or pain, burning with urination and vaginal discharge that typically does not smell. It is most commonly caused via excessive growth of one of a family of fungus known as candida. They are normally present in the vagina in small numbers and usually harmless. It is not known exactly how changes in the vagina trigger thrush, but it may be due to a hormone (chemical) imbalance. In most cases, the cause of the hormonal changes is unknown.
   Whilst vulvovaginal candidiasis is caused via the yeast Candida, there are many predisposing factors. Symptoms of thrush can also be caused via Candida glabrata, Candida krusei, Candida parapsilosis, and Candida tropicalis. Nonalbican Candida are commonly found in complicated cases of vaginal thrush such that first line treatment is ineffective. These cases are more likely in those who are immunocompromised.

 Medication

   Infection occurs within about 30 per cent of females who are taking a course of antibiotics orally. The evidence of the effect of oral contraceptives is controversial, and yet not clarified.

Pregnancy
   During gestation, changes in the levels of female sex hormones, such as oestrogen, make a female more likely to develop a yeast infection. During the gestational period, the Candida fungus is more prevalent (common), and recurrent infection is also more likely. There is no clear evidence that treatment of asymptomatic candidal vulvovaginitis in pregnancy reduces the risk of preterm birth.

Lifestyle
   Infections often occur devoid of sex and cannot be related to frequency of intercourse. Personal hygiene methods or tight-fitting clothing, such as tights and thong underwear, do not appear to increase the risk, either.

Diseases
   Those with poorly controlled diabetes have increased rates of infection while those with well controlled diabetes do not. The risk of developing thrush is also increased in an immunodeficiency, for example, by an immunosuppressive condition, such as HIV or AIDS, or receiving chemotherapy. This is because in these circumstances the body’s immune system, which usually fights off infection, is unable to effectively control the spread of the Candida fungus.

Diagnosis:
   Vulvovaginal candidosis is the presence of Candida in addition to vaginal inflammation. The presence of yeast is typically diagnosed in one of three ways: vaginal wet mount microscopy, microbial culture, and antigen tests. It may be described as being uncomplicated or complicated.

Uncomplicated
   Uncomplicated thrush is where only a single episode of thrush or less than four episodes occurs in a year. Thrush is described as uncomplicated if the symptoms are mild or moderate, and caused by the Candida albicans fungus.

 —Complicated
   Complicated thrush is four or more episodes of thrush in a year or when severe symptoms of vulvovaginal inflammation are experienced. Thrush may also be described as complicated if coupled with pregnancy, poorly controlled diabetes, an immunodeficiency, or the thrush is not caused via the Candida albicans fungus.

 

Treatment

The following are alternatives of recommended regimens:
   Intravaginal agents: butoconazole, clotrimazole, miconazole, nystatin, tioconazole, terconazole. Candidal vulvovaginitis in pregnancy should be treated with intravaginal clotrimazole or miconazole for at least 7 days. Oral Agent: fluconazole as a single dose. Short-course topical formulations (Id est, single dose and regimens of 1–3 days) effectively treat uncomplicated candidal vulvovaginitis. The topically applied azole drugs are more effective than nystatin. Treatment with azoles results in relief of symptoms and negative cultures in 80–90 per cent of patients who complete therapy. The creams and suppositories in this regimen are oil-based and might weaken latex condoms and diaphragms. Treatment for vagina thrush using antifungal medication is ineffective in up to 20 per cent of cases. Treatment for thrush is considered to have failed if the symptoms do not clear within 7–14 days. There are a number of reasons for treatment failure. For example, if the infection is a different kind, such as bacterial vaginitis (the most common cause of abnormal vaginal discharge), rather than thrush.

Sources: 

Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.

Goldacre MJ, Watt B, Loudon N, et al. Vaginal microbial flora in normal young women. Br Med J 1979; 1:1450.

Tibaldi C, Cappello N, Latino MA, et al. Vaginal and endocervical microorganisms in symptomatic and asymptomatic non-pregnant females: risk factors and rates of occurrence. Clin Microbiol Infect 2009; 15:670.

Berg AO, Heidrich FE, Fihn SD, et al. Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology. JAMA 1984; 251:620.

Geiger AM, Foxman B, Gillespie BW. The epidemiology of vulvovaginal candidiasis among university students. Am J Public Health 1995; 85:1146.

Foxman B, Muraglia R, Dietz JP, et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 2013; 17:340.

Odds, FC. Candidosis of the genitalia. In: Odds, FC. Candida and candidosis: A review and bibliography, 2nd ed, Bailliére Tindall, London 1988, p. 124.

Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961.

Horowitz BJ, Giaquinta D, Ito S. Evolving pathogens in vulvovaginal candidiasis: implications for patient care. J Clin Pharmacol 1992; 32:248.

Vermitsky JP, Self MJ, Chadwick SG, et al. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008; 46:1501.

Sobel JD, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol 1996; 34:2497.

McClelland RS, Richardson BA, Hassan WM, et al. Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. J Infect Dis 2009; 199:1883.

Vitali B, Pugliese C, Biagi E, et al. Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. Appl Environ Microbiol 2007; 73:5731.

Zhou X, Westman R, Hickey R, et al. Vaginal microbiota of women with frequent vulvovaginal candidiasis. Infect Immun 2009; 77:4130.

Bertholf ME, Stafford MJ. Colonization of Candida albicans in vagina, rectum, and mouth. J Fam Pract 1983; 16:919.

Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985; 152:924.

Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178:203.

Merson-Davies LA, Odds FC, Malet R, et al. Quantification of Candida albicans morphology in vaginal smears. Eur J Obstet Gynecol Reprod Biol 1991; 42:49.

Vazquez JA, Sobel JD, Demitriou R, et al. Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis 1994; 170:1566.

Lockhart SR, Reed BD, Pierson CL, Soll DR. Most frequent scenario for recurrent Candida vaginitis is strain maintenance with “substrain shuffling”: demonstration by sequential DNA fingerprinting with probes Ca3, C1, and CARE2. J Clin Microbiol 1996; 34:767.

Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92:43.

Donders GG, Babula O, Bellen G, et al. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008; 115:1225.

Babula O, Lazdāne G, Kroica J, et al. Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40:1258.

Ip WK, Lau YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2004; 190:632.

Lillegard JB, Sim RB, Thorkildson P, et al. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 2006; 193:1589.

Giraldo PC, Babula O, Gonçalves AK, et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007; 109:1123.

Foxman B. The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health 1990; 80:329.

Sobel, JD. Candida vaginitis. Infect Dis Clin Pract 1994; 3:334.

Donders GG. Lower Genital Tract Infections in Diabetic Women. Curr Infect Dis Rep 2002; 4:536.

de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002; 2:1.

Ray D, Goswami R, Banerjee U, et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007; 30:312.

Wilton L, Kollarova M, Heeley E, Shakir S. Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. Drug Saf 2003; 26:589.

Pirotta M, Gunn J, Chondros P, et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. BMJ 2004; 329:548.

Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 2003; 101:548.

Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996; 7:182.

Bradshaw CS, Morton AN, Garland SM, et al. Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol 2005; 106:105.

Reed BD, Zazove P, Pierson CL, et al. Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis. J Womens Health (Larchmt) 2003; 12:979.

Patel DA, Gillespie B, Sobel JD, et al. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am J Obstet Gynecol 2004; 190:644.

Heidrich FE, Berg AO, Bergman JJ. Clothing factors and vaginitis. J Fam Pract 1984; 19:491.

Elegbe IA, Elegbe I. Quantitative relationships of Candida albicans infections and dressing patterns in Nigerian women. Am J Public Health 1983; 73:450.

Heng LS, Yatsuya H, Morita S, Sakamoto J. Vaginal douching in Cambodian women: its prevalence and association with vaginal candidiasis. J Epidemiol 2010; 20:70.

Corsello S, Spinillo A, Osnengo G, et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003; 110:66.

Spinillo A, Pizzoli G, Colonna L, et al. Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol 1993; 81:721.

Farage M, Bramante M, Otaka Y, Sobel J. Do panty liners promote vulvovaginal candidiasis or urinary tract infections? A review of the scientific evidence. Eur J Obstet Gynecol Reprod Biol 2007; 132:8.

Janković S, Bojović D, Vukadinović D, et al. Risk factors for recurrent vulvovaginal candidiasis. Vojnosanit Pregl 2010; 67:819.

Fidel PL Jr, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996; 9:335.

Fong IW. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992; 68:174.

Shihadeh AS, Nawafleh AN. The value of treating the male partner in vaginal candidiasis. Saudi Med J 2000; 21:1065.

Bisschop MP, Merkus JM, Scheygrond H, van Cutsem J. Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study. Br J Obstet Gynaecol 1986; 93:79.

Colli E, Landoni M, Parazzini F. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourin Med 1997; 73:267.

Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA 2004; 291:1368.

Eckert LO. Clinical practice. Acute vulvovaginitis. N Engl J Med 2006; 355:1244.

Eckert LO, Hawes SE, Stevens CE, et al. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 1998; 92:757.

Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997; 24:649.

Mendling W, Brasch J, German Society for Gynecology and Obstetrics, et al. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses 2012; 55 Suppl 3:1.

National guideline for the management of vulvovaginal candidiasis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75 Suppl 1:S19.

SWARTZ JH, LAMKINS BE. A RAPID, SIMPLE STAIN FOR FUNGI IN SKIN, NAIL SCRAPINGS, AND HAIRS. Arch Dermatol 1964; 89:89.

Sobel JD, Subramanian C, Foxman B, et al. Mixed vaginitis-more than coinfection and with therapeutic implications. Curr Infect Dis Rep 2013; 15:104.

Dan M, Leshem Y, Yeshaya A. Performance of a rapid yeast test in detecting Candida spp. in the vagina. Diagn Microbiol Infect Dis 2010; 67:52.

Chatwani AJ, Mehta R, Hassan S, et al. Rapid testing for vaginal yeast detection: a prospective study. Am J Obstet Gynecol 2007; 196:309.e1.

Marot-Leblond A, Nail-Billaud S, Pilon F, et al. Efficient diagnosis of vulvovaginal candidiasis by use of a new rapid immunochromatography test. J Clin Microbiol 2009; 47:3821.

Hopwood V, Evans EG, Carney JA. Rapid diagnosis of vaginal candidosis by latex particle agglutination. J Clin Pathol 1985; 38:455.

Matsui H, Hanaki H, Takahashi K, et al. Rapid detection of vaginal Candida species by newly developed immunochromatography. Clin Vaccine Immunol 2009; 16:1366.

Abbott J. Clinical and microscopic diagnosis of vaginal yeast infection: a prospective analysis. Ann Emerg Med 1995; 25:587.

Tabrizi SN, Pirotta MV, Rudland E, Garland SM. Detection of Candida species by PCR in self-collected vaginal swabs of women after taking antibiotics. Mycoses 2006; 49:523.

Diba K, Namaki A, Ayatolahi H, Hanifian H. Rapid identification of drug resistant Candida species causing recurrent vulvovaginal candidiasis. Med Mycol J 2012; 53:193.

Mahmoudi Rad M, Zafarghandi ASh, Amel Zabihi M, et al. Identification of Candida species associated with vulvovaginal candidiasis by multiplex PCR. Infect Dis Obstet Gynecol 2012; 2012:872169.

Weissenbacher T, Witkin SS, Ledger WJ, et al. Relationship between clinical diagnosis of recurrent vulvovaginal candidiasis and detection of Candida species by culture and polymerase chain reaction. Arch Gynecol Obstet 2009; 279:125.

Ferris DG, Dekle C, Litaker MS. Women’s use of over-the-counter antifungal medications for gynecologic symptoms. J Fam Pract 1996; 42:595.

Ferris DG, Nyirjesy P, Sobel JD, et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002; 99:419.

Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:662.

Reef SE, Levine WC, McNeil MM, et al. Treatment options for vulvovaginal candidiasis, 1993. Clin Infect Dis 1995; 20 Suppl 1:S80.

Watson MC, Grimshaw JM, Bond CM, et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2001; :CD002845.

Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 1995; 172:1263.

Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.

Houang ET, Chappatte O, Byrne D, et al. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother 1990; 34:909.

Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996; 22:726.

Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001; 185:363.

Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003; 189:1297.

United Kingdom National Guideline on the Management of Vulvovaginal Candidiasis (2007). Available at www.bashh.org/documents/1798. (Accessed December 4, 2008).

Cotch MF, Hillier SL, Gibbs RS, Eschenbach DA. Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol 1998; 178:374.

Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev 2001; :CD000225.

Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 2005; 73:919.

FDA Drug Safety Communication:Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants http://www.fda.gov/Drugs/DrugSafety/ucm266030.htm (Accessed on September 21, 2011).

Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 2013; 369:830.

Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999; 19:221.

Sorensen HT, Nielsen GL, Olesen C, et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol 1999; 48:234.

Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol 1994; 46:115.

Mastroiacovo P, Mazzone T, Botto LD, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996; 175:1645.

Nørgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother 2008; 62:172.

Wilton LV, Pearce GL, Martin RM, et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998; 105:882.

Sobel JD. Management of patients with recurrent vulvovaginal candidiasis. Drugs 2003; 63:1059.

Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 351:876.

Donders G, Bellen G, Byttebier G, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008; 199:613.e1.

Marchaim D, Lemanek L, Bheemreddy S, et al. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012; 120:1407.

Danby CS, Boikov D, Rautemaa-Richardson R, Sobel JD. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. Antimicrob Agents Chemother 2012; 56:1403.

CLSI. Performance standards for antimibrobial susceptibility testing. Nineteenth informational supplement. Approved standard M100–S19. Wayne (PA): Clinical and Laboratory Standards Institute; 2009.

Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992; 116:353.

Shalev E, Battino S, Weiner E, et al. Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. Arch Fam Med 1996; 5:593.

Collins EB, Hardt P. Inhibition of Candida albicans by Lactobacillus acidophilus. J Dairy Sci 1980; 63:830.

Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicrob Chemother 2006; 58:266.

Martinez RC, Franceschini SA, Patta MC, et al. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol 2009; 48:269.

Witt A, Kaufmann U, Bitschnau M, et al. Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. BJOG 2009; 116:1499.

White DJ, Johnson EM, Warnock DW. Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med 1993; 69:112.

Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt) 2011; 20:1245.

Rigg D, Miller MM, Metzger WJ. Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990; 162:332.

Magliani W, Conti S, Cassone A, et al. New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol Med 2002; 8:121.

American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.

Fluconazole. Drugs in Pregnancy and Lacation. 8th edition. http://wk-trusted-auth.ipublishcentral.com/services/trustedauth/reader/isbn/9780781778763 (Accessed on February 07, 2013).

Candiasis (vulvovaginal). http://clinicalevidence.bmj.com

To conclude this wondrous journey, I’d like to state that I have never once myself witnessed such a thing where males spread their legs to oppress females or to take up more space, in fact from seeing all of this blow up over the internet it seems to be central to the Good Ol’ US of A.

I believe the term I’m looking for is “rekt”.

The amount of rekt is a little too much.